Terminology Service for NFDI4Health
JSON

Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine

Go to external page http://purl.obolibrary.org/obo/NCIT_C70674

A peptide vaccine preparation, containing recombinant human epidermal growth factor (rEGF) linked to the Neisseria meningitidis-derived recombinant immunogenic carrier protein P64k (rP64k) and mixed with the immunoadjuvant Montanide ISA 51, with potential active immunotherapy activity. Recombinant human EGF-rP64K/Montanide ISA 51 vaccine may trigger a humoral immune response against vaccine rEGF and rP64K and, so, against endogenous EGF. Antibody-mediated inhibition of endogenous EGF binding to its receptor, epithelial growth factor receptor (EGFR), may result in the inhibition of tumor cell proliferation. [ ]

Term info

Label

Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine

Synonyms
  • CIMAvax EGF
  • CIMAvax Epidermal Growth Factor Vaccine
  • CIMAvax-EGF
  • Center of Molecular Immunology (CIMA) Epidermal Growth Factor (EGF) Vaccine
  • Center of Molecular Immunology Epidermal Growth Factor Vaccine
  • CimaVax
  • CimaVax Vaccine
  • Cimavax
  • Recombinant Human EGF-P64K/Montanide Vaccine
  • Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine
Subsets

NCIT_C116978, NCIT_C128784, NCIT_C116977, NCIT_C157711, NCIT_C157712

Display Name

Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine

Legacy Concept Name

Recombinant_Human_EGF-rP64K_Montanide_ISA_51_Vaccine

NCI META CUI

CL376048

Preferred Name

Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine

Semantic Type

Pharmacologic Substance, Amino Acid, Peptide, or Protein

code

C70674